Intervention Review

You have free access to this content

Anthracycline-containing regimens for treatment of follicular lymphoma in adults

  1. Gilad Itchaki1,*,
  2. Anat Gafter-Gvili2,
  3. Meir Lahav3,
  4. Liat Vidal2,
  5. Pia Raanani1,
  6. Ofer Shpilberg1,
  7. Mical Paul4

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 7 JUL 2013

Assessed as up-to-date: 17 APR 2013

DOI: 10.1002/14651858.CD008909.pub2


How to Cite

Itchaki G, Gafter-Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M. Anthracycline-containing regimens for treatment of follicular lymphoma in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD008909. DOI: 10.1002/14651858.CD008909.pub2.

Author Information

  1. 1

    Beilinson Hospital, Rabin Medical Center, Institute of Hematology, Davidoff Center, Petah Tikva, Israel

  2. 2

    Beilinson Hospital, Rabin Medical Center, Department of Medicine E, Petah Tikva, Israel

  3. 3

    Beilinson Hospital, Rabin Medical Center, Department of Medicine A, Petah Tikva, Israel

  4. 4

    Rambam Health Care Center. Haifa, Israel and Sackler Faculty of Medicine, Unit of Infectious Diseases, Tel Aviv, Israel

*Gilad Itchaki, Institute of Hematology, Davidoff Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, 49100, Israel. giladi@clalit.org.il. gilad14@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 7 JUL 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.1 Overall survival.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.3 Mortality at 3 years.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.5 Complete response.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.7 Disease control.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.8 Progression or relapse at 3 years.
[Figure 8]
Figure 8. Forest plot of comparison: 1 Anthracycline versus no anthracycline same chemotherapy, outcome: 1.10 Infection.
[Figure 9]
Figure 9. Forest plot of comparison: 4 Comparison of different anthracyclines, outcome: 4.2 Disease control.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 1 Overall survival.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 2 Overall survival with Zinzani.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 3 Mortality at 3 years.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 4 Mortality at 5 years.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 5 Complete response.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 6 Overall response.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 7 Disease control.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 8 Progression/relapse at 3 years.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 9 Neutropenia grade 3-4.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Anthracycline versus no anthracycline same chemotherapy, Outcome 10 Infection.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Sensitivity analysis for allocation concealment, Outcome 1 Overall survival.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Sensitivity analysis for allocation concealment, Outcome 2 Disease control.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Sensitivity analysis for second randomization, Outcome 1 Disease control.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Comparison of different anthracyclines, Outcome 1 Overall survival.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Comparison of different anthracyclines, Outcome 2 Disease control.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 1 Overall survival.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 2 Mortality at 3 years.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 3 Complete response.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Anthracycline versus no anthracycline different chemotherapy, Outcome 4 Disease control.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Cardiotoxicity for all studies, Outcome 1 Cardiotoxicity.